TMO Stock Likely to Gain From New International CorEvitas AD Registry
Thermo Fisher Scientific TMO announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients. The registry fills a significant gap for real-world evidence and adolescent-specific developmental and safety data related to novel therapies for AD, complementing the existing adult CorEvitas AD Registry launched in 2020.
CorEvitas, acquired in August 2023, is part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.
Predicting TMO Stock Movement Following the News
Since the announcement, Thermo Fisher’s shares edged down 0.2% to close at $612.94 yesterday. However, we are optimistic about the acquisition of CorEvitas, which has expanded the PPD clinical research business with highly complementary real-world evidence solutions, helping to enhance decision-making and the time and cost of drug development. The business is performing well and positively, impacting both customers and patients. Accordingly, we anticipate the latest development to positively boost the market sentiment toward the stock.
Thermo Fisher currently has a market capitalization of $233.2 billion. The company has an earnings yield of 3.6%, outperforming the industry’s -5.3%. In the last reported quarter, it has delivered an earnings beat of 4.7%.
More on Thermo Fisher’s New Registry
AD, also known as pediatric eczema, is a chronic skin condition that affects babies and children and is particularly challenging during adolescence due to its impact on appearance and self-esteem. The latest CorEvitas registry – the company’s 11th independent registry – will allow the prospective evaluation of adolescent AD patients to better understand the disease and the treatment pathway.
Image Source: Zacks Investment Research
It will collect detailed prospective data to generate evidence for comparative safety and effectiveness research, including an in-depth assessment of the evolution of comorbid medical conditions, growth and maturation milestones. During registry visits, granular, clinician-reported outcomes measures will be collected, such as body surface area involvement and SCORing Atopic Dermatitis, along with patient-reported outcomes assessing symptom impact and quality of life.
The registry recently enrolled its first patient in the European Union, expanding its footprint beyond North America, where the first patient was enrolled in December 2023. CorEvitas services include proprietary autoimmune and inflammatory disease registries containing structured, regulatory-grade patient clinical data across 400 investigator sites and over 100,000 patients followed longitudinally.
Industry Prospects Favor Thermo Fisher
Per a Research report, the global AD drugs market was valued at $14.19 billion in 2022 and is expected to grow at a compound annual rate of 8.4% through 2030. The growing prevalence of AD, strong pipeline, emergence of biologics and untapped opportunities are expected to boost the market’s growth. Several companies are investing in research and development to develop novel products to capture more shares in the lucrative market.
More Updates from Thermo Fisher
Last month, Thermo Fisher’s PPD business expanded its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. The new facility will serve pharmaceutical and biotech customers with advanced laboratory services and leading-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide.
TMO Stock Price Performance
In the past six months,TMO shares have increased 6.4% compared with the industry’s rise of 3.6%.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 63.3% in the past year. Estimates for the company’s earnings per share (EPS) have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 175.2% in the past year compared with the industry’s growth of 17.6%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for Phibro Animal Health’s EPS have risen 0.7% in 2024 in the past 30 days. Shares of the company have rallied 77% in the past year compared with the industry’s 20.6% growth. PAHC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.1%. In the last reported quarter, it delivered an earnings surprise of 20.6%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
AxoGen, Inc. (AXGN) : Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report